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ABSTRACT
Aims: Structured multicentre efforts are needed if the
prognosis of adrenocortical carcinoma (ACC) is to be
improved. Data collection may be enhanced through
standardised histopathological reporting using criteria
such as the recently published Royal College of
Pathologists’ (UK) minimum dataset (MDS). This study
aimed to perform a clinicopathological review of the adult
patients treated at the Royal Victoria Infirmary, Newcastle
upon Tyne, in the 10 years preceding the MDS.
Methods: Case records were examined for all patients
diagnosed with ACC between 1996 and 2006. Pathology
was reviewed and compared with the Royal College of
Pathologists’ MDS along with the original reports. A
systematic evaluation of Ki-67 immunolabelling was also
performed.
Results: Eleven patients with ACC were diagnosed and
treated. Histopathological reporting according to the MDS
identified more features of malignancy than in the original
reports (8.5¡1.2 versus 5.1¡0.8, p,0.02). The median
number of microscopic criteria of malignancy was 7
(range 5–10), with>5 features occurring in all cases. The
most commonly observed features of malignancy were
diffuse architecture, ,25% clear cells, confluent necrosis,
abnormal mitoses and mitotic count >6 per 50 high-
power fields. Capsular invasion and >8 MDS criteria of
malignancy were associated with a worse outcome (each
p,0.01). Median Ki-67 index was 19.0% (range 3.7–
44.1%) and was not apparently related to survival.
Conclusions: Standardised criteria for histopathological
reporting of ACC will improve the accuracy of data for
cancer registration and may also assist in individual
patient stratification. An elevated Ki-67 index is a feature
of ACC, although it does not appear to predict individual
patient survival.
Adrenocortical carcinoma (ACC) is a highly
aggressive malignancy. Metastatic spread is com-
mon at presentation (21–52%) and almost invari-
able on follow up.1–4 All current medical and
surgical treatments carry poor results. For
instance, the average survival after diagnosis is
only 10–22 months4–6 and 5-year survival rates
vary between 16% and 38% (see review7). One of
the major restrictions to improving the treatment
for ACC is the infrequency of its occurrence,
with an incidence of 1–2 per million population
per year.8 9 Thus, even single tertiary care centres
may see and treat only one or two patients each
year. Accordingly, multicentre collaborations are
essential if the prognosis is to be improved. One
of the major limitations in this regard has been
the lack of standardised data collection between
centres.
The histological diagnosis of malignancy in
resected adrenocortical neoplasms can be proble-
matic and various combinations of criteria have
been proposed.10–13 In 2006, the Royal College of
Pathologists (UK) ((RCPath(UK)) produced a
minimum dataset (MDS) for histopathology
reports of ACC, based mainly on the Weiss
criteria.14 The MDS also includes comment on
involvement of versus clear surgical margins (ie,
apparent completeness of resection) and, by
encouraging accurate diagnosis and SNOMED
coding, it should improve data accuracy for cancer
registration. The value of these histological fea-
tures in predicting outcome and guiding adjuvant
therapy has yet to be appraised. Several groups
have demonstrated the apparent role of Ki-67
(MIB-1 clone) immunostaining in differentiating
benign from malignant adrenocortical neoplasms15–
18 and in predicting outcome in malignancy.19
Nevertheless, a Ki-67 index is not a criterion
included in the current MDS.
This clinicopathological review aimed to retro-
spectively test the completeness and accuracy of
pathological reporting of features listed in the
MDS, and to assess the performance of these
features and the Ki-67 index in predicting survival
for patients with ACC at one centre over 10 years.
METHODS
Histopathology records were interrogated to find
all patients who attended the Royal Victoria
Infirmary, Newcastle upon Tyne, UK, and who
had a diagnosis of ACC made between 1996 and
2006. Patient clinical records were reviewed for age,
sex, mode of presentation, pre- and postoperative
biochemical and imaging evaluation, and treat-
ment and outcome.
Staging of disease was based on the McFarlane/
Sullivan classification:20 stage I, tumour ,5 cm
with negative nodes, no local invasion and no
metastases; stage II, tumour .5 cm with negative
nodes, no local invasion and no metastases; stage
III, tumour with positive nodes or local invasion;
and stage IV, tumour with positive nodes and local
invasion or distant metastases. Stage of disease was
based on imaging, intraoperative and pathological
findings.
Serum cortisol and testosterone (T) were mea-
sured using a competitive chemiluminescence
immunoassay (Advia Centaur System, Bayer
Diagnostics, Newbury, UK). Follicle stimulating
hormone (FSH) and luteinising hormone (LH)
were measured by a two-site sandwich chemilu-
minescence immunoassay (Advia). Urine cortisol
was determined by competitive radioimmunoassay
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(Orion Diagnostica, Oy, Finland). Dehydroepiandrosterone
(DHEAS) and androstenedione were measured by competitive
chemiluminscence immunoassay on a DPC Immulite 2000
analyser (DPC, Gwynedd, UK). Oestrone and oestradiol were
measured by in-house radioimmunoassay (Leeds SAS steroid
centre, UK).
The original histopathology reports were reviewed against the
RCPath(UK) MDS. For this evaluation, the reports from two
further patients with ACC, treated at another hospital nearby,
were also included. The histology slides underwent masked
independent review by two pathologists (MSG and SJJ) for
features within the MDS including apparent completeness of
resection. Differences were resolved by consensus.
Immunohistochemistry for Ki-67 was performed retrospectively
on formalin-fixed paraffin-embedded tissue using MIB-1 anti-
body (Dako, Cambridgeshire, UK) at 1 in 300 dilution incubated
in Dako autostainer for 30 min at room temperature after pre-
treatment by pressure cooking in citrate buffer (Menapath,
Menarini Diagnostics, Berkshire, UK). The Ki-67 labelling index
was assessed independently by the two pathologists. The index
was calculated as the percentage of positively stained nuclei out
of a minimum of 1000 tumour cell nuclei, and the mean of the
two observations was taken.
Statistical analysis
The relationship between the presence of histopathological
features and survival was determined by log-rank test and the
difference in microscopic features of malignancy on original
reports and re-review was determined by paired Student t test.
All statistics were done using GraphPad Prism version 3.00 for
Windows (GraphPad Software, San Diego, California, USA).
RESULTS
Clinical presentation and endocrine evaluation
Eleven adult patients were diagnosed with ACC at our hospital
between 1996 and 2006 (six women, median age of presentation
47 years (range 28–80 years)). The clinical and endocrinological
features of each patient are shown in table 1. Autonomous
hormone hypersecretion was responsible for the presenting
features in seven patients and the most common mode of
presentation was with classical features of Cushing syndrome.
The median duration of symptoms in all patients presenting
with any hormonal manifestations was 3 months (range
1 month to 1 year). There was no relationship between tumour
functionality and outcome.
Surgical treatment and extent of disease
Table 2 shows the extent of disease at surgery and on
radiological follow-up. Initial assessment of tumour spread by
preoperative imaging (ultrasound scan, CT or MRI) and by
intraoperative inspection at the time of surgery revealed the
presence of definite metastasis in just two patients (table 2).
Open adrenalectomy was performed in 10 patients, with one
individual (patient I) undergoing laparascopic adrenalectomy.
On follow-up, nine patients had radiological evidence of intra-
abdominal disease recurrence, with local recurrence in the
adrenal bed occurring in four patients, all of whom had had
involvement of the original specimen margins (table 2).
Medical treatment
Nine patients received mitotane and three patients received
combination chemotherapy (table 2). Despite the attainment of
adequate plasma mitotane levels, radiological evidence of a
reduction in tumour bulk was present in only two individuals.
Reported adverse events on mitotane included gastrointestinal
disturbance, dizziness, fixed drug eruption with gynaecomastia,
and drug-induced hepatitis.
Survival
Four patients are still alive, of whom only two are free from any
evidence of residual or metastatic disease (table 2). Of the seven
patients who have died the median survival from presentation
was 579 days (range 162–3127 days).
Pathology
Median tumour weight was 171 g (range 41–1600 g) and
median greatest tumour dimension was 85 mm (57–190 mm).
Thus, all patients had at least stage II disease. We did not find a
relationship between tumour dimension or weight and out-
come. Table 3 shows the histological features according to the
RCPath(UK) MDS as found on review of the slides. Table 2
shows the Ki-67 indices for proliferation. There was good
agreement between the two observers for Ki-67 (mean¡SD for
difference in observer scores, 3.7¡2.2%). The median Ki-67
index was 19.0% (range 3.7–44.1%). There was no significant
relationship between Ki-67 index and either duration of
symptoms prior to diagnosis or outcome.
On histopathological review, the number of MDS micro-
scopic features suggestive of malignancy present in cases ranged
from 5–10 (median 7) (for Weiss criteria the median was 6
(range 4–8)) (table 3). Thus, all patients had at least five
histological features suggestive of malignancy. The five most
commonly observed features of malignancy were diffuse
architecture, less than 25% clear cells, confluent necrosis,
abnormal mitoses and a mitotic count of six or more per 50
high-power fields (table 3). Sinusoidal invasion was not
observed in any of the patients. The presence of (7 MDS
microscopic features of malignancy (p,0.01) and the absence of
capsular invasion (p,0.01) were both associated with an
improved survival (fig 1).
Original reporting of features of malignancy
The original histopathology reports were reviewed to determine
whether each microscopic feature of malignancy had been
commented on in the initial account. In addition to the 11
patients under medical care at our centre, tissue and reports
were available for two further patients treated at a neighbouring
hospital, and these were included in this analysis. Table 4 shows
that only the presence or absence of capsular and extra-adrenal
invasion were commented on in all cases in the original reports.
Of the five most commonly occurring microscopic features,
,25% clear cells, confluent necrosis and abnormal mitoses were
commented on in less than 75% of the original reports (table 4).
Re-review of the tissue sections, according to the MDS criteria,
not only resulted in more comprehensive reporting but also
identified the presence of significantly more microscopic
features of malignancy (table 4). For instance, taking into
account all 11 of the MDS criteria, the mean (¡SEM) number
of times any feature was present on the original report was
5.1¡0.8 and on review it was 8.5¡1.2 (p,0.02).
DISCUSSION
ACC is an aggressive malignancy with poor long-term survival.
Low tumour incidence is a major obstacle to identifying
effective treatment regimens and accurate prognostic markers.
This situation is further compounded by the varied clinical
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manifestations of the disease and its somewhat unpredictable
natural history. Introduction and adherence to standardised
microscopic criteria such as the MDS, or Weiss criteria, will lead
to more complete histopathological documentation that should
impact positively on cancer registration, and possibly also on
individual patient prognostication.
Our series illustrates the variety of ways in which an adult
patient with ACC may present. Tumour hyperfunctionality
occurred in the majority of cases and manifested most
commonly as Cushing syndrome. We did not find a relationship
between tumour functionality and outcome, which despite the
suggestions of some authors21 22 is consistent with the findings
of most studies to date (see review 8).
Historically, gross examination of the tumour has assisted in
the diagnosis of ACC in the presence of haemorrhage or necrosis
or if the tumour is especially large.20 However, with the advent
of highly sensitive imaging modalities such as CT and MRI,
adrenal tumours are often now identified at a smaller size and,
accordingly, standardised histological criteria for malignancy
have been advocated. In 1984, Weiss proposed a series of nine
histological criteria for adults, with the presence of four (later
re-defined to three) or more indicating that a tumour was
ACC.12 13 In 2006, the RCPath(UK) MDS for ACC expanded
these criteria with the addition of the presence of ‘‘broad fibrous
bands’’ and ‘‘extra-adrenal invasion’’ and re-classified the term
high nuclear grade to ‘‘significant nuclear pleomorphism’’.14 In
our series, all cases demonstrated at least five criteria for
malignancy with two microscopic features (greater than one-
third diffuse architecture and less than 25% clear cells) present
in all cases.
While microscopic criteria are undoubtedly of benefit in
establishing a diagnosis of malignancy, their role in predicting
outcome for patients is a little more contentious. Some studies
have demonstrated an inverse relationship between mitotic
count and survival.23 24 However, the results in our patients
correspond with those of Wachjenberg et al,8 with no associa-
tion found. Indeed, only two of our patients had a mitotic rate
,6 per 50 high-power fields, both subsequently developing
distant metastases. By way of contrast, the total number of
MDS microscopic features of malignancy and the presence of
capsular invasion were predictive of a worse outcome.
Recently, there has been considerable interest in the use of
alternative markers of cellular proliferation to predict malig-
nancy and to be used as indicators of prognosis. Proliferating cell
Table 1 Clinical and biochemical data for 11 patients with adrenocortical carcinoma
Patient Sex
Age
(years)
Clinical
presentation
Biochemical evidence
of cortisol secretion
Biochemical evidence of
androgen/oestrogen
secretion
Combined
hormone
secretion
(yes/no)
Post-operative
biochemical testing
A M 45 Mass effect Not tested Not tested Not tested O/N DST, serum cortisol
38 nmol/l
B F 28 Oligomenorrhoea UFC:creatinine ratio 28.5
and 38.0 nmol/mmol
T 3.1 nmol/l, LH 16.1 U/l,
FSH 3.3 IU/l, DHEAS
2.9 mmol/l,
androstenedione
19.9 nmol/l
No Not tested
C F 41 Virilisation Not tested T 43.8 nmol/l,
DHEAS 36.5 mmol/l,
androstenedione
76.0 nmol/l
Yes UFC 2690 and
1980 nmol/24 h,
T 42.2 nmol/l
D F 42 Cushing
syndrome with
hirsutism
UFC 3296, 4416 and
6375 nmol/24 h
T 6.8 nmol/l Yes UFC 1694 nmol/24 h,
T 7.2 nmol/l,
androstenedione 23 nmol/l
E M 62 Cushing
syndrome
UFC 364, 442 and
914 nmol/24 h
Not tested: no clinical
features of
feminisation
No UFC 159 nmol/24 h
O/N DST, serum cortisol
442 nmol/l,
oestradiol 234 pmol/l
F F 46 Cushing
syndrome with
hirsutism
LDDST, serum cortisol 559 nmol/l;
HDDST, serum cortisol
555 nmol/l
T 7.2 nmol/l Yes UFC:creatinine ratio 4.8,
9.8 and 9.1 nmol/mmol,
T 0.2 nmol/l
G M 54 Feminisation LDDST, serum cortisol
291 nmol/l
Oestrone 821 pmol/l,
oestradiol 797 pmol/l
Yes O/N DST, serum cortisol
,24 nmol/l,
oestrone 95 pmol/l,
oestradiol 109 pmol/l
H M 66 Incidental finding
on MRI
UFC 2867 nmol/l;
O/N DST, serum cortisol
768 nmol/l
Not tested: no clinical
features of feminisation
No UFC 6803, 5388
and 8666 nmol/24 h
I M 80 Cushing
syndrome
UFC 2584 and 4509 nmol/24 h;
LDDST, serum cortisol 864 nmol/l;
HDDST, serum cortisol 828 nmol/l
Not tested: no clinical
features of feminisation
No O/N DST, serum cortisol
555 nmol/l
J F 65 Cushing
syndrome with
hirsutism
UFC 568 nmol/24 h,
LDDST and HDDST reported
from another hospital
as non-suppressing
T 5.2 nmol/l Yes UFC 963, 741 and 1920 nmol/24 h;,
LDDST, serum cortisol 566 nmol/l;
T 3.0 nmol/l
K F 47 Mass effect Not tested Not tested Not tested LDDST, serum cortisol 35 nmol/l;
T 0.7 nmol/l
DHEAS, dehydroepiandrosterone; HDDST, high-dose dexamethasone suppression test (2 mg dexamethasone orally, six-hourly for 48 h); LDDST, low-dose dexamethasone
suppression test (0.5 mg dexamethasone orally, six-hourly for 48 h); O/N DST, 1.5 mg overnight dexamethasone suppression test; T, testosterone; UFC, urinary free cortisol.
Reference ranges: androstenedione 0–13 nmol/l, DHEAS 1.4–11.1 mmol/l, FSH 1–10 IU/l, LH 2–12 U/l, oestradiol 0–180 pmol/l, oestrone,330 pmol/l, random serum cortisol 190–
650 nmol/l, T 0–3.2 nmol/l, UFC 0–320 nmol/24 h, UFC/creatinine ratio 5–55 nmol/mmol.
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nuclear antigen has not been shown to differ between benign
and malignant adrenal tumours25 and gradation of staining
means it can be difficult to distinguish positive and negative
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Figure 1 Survival curves according to number of Royal College of
Pathologists’ (UK) minimum dataset (MDS) microscopic criteria of
malignancy (A) and presence or absence of capsular invasion (B).
Table 4 Comprehensiveness of reporting of microscopic features of
malignancy in original reports from 13 patients with ACC, prior to the
introduction of the Royal College of Pathologists’ (UK) minimum dataset
Microscopic
feature
Presence or absence of
feature documented in
original report (%)
Feature documented
as present in
original reports (%)
Feature
present on
review (%)
.1/3 diffuse
architecture*
10 (77) 10 (77) 13 (100)
,25% clear cells* 3 (23) 3 (23) 13 (100)
Significant nuclear
pleomorphism*
12 (92) 6 (46) 8 (61)
Confluent necrosis* 9 (69) 7 (54) 12 (92)
Mitoses >6 per
HPF (6400)*
10 (77) 7 (54) 10 (77)
Abnormal mitoses* 7 (54) 5 (38) 11 (85)
Broad fibrous bands 2 (15) 1 (8) 9 (69)
Capsular invasion* 13 (100) 8 (61) 6 (46)
Venous invasion* 12 (92) 5 (38) 7 (54)
Sinusoidal invasion* 6 (46) 2 (15) 1 (8)
Extra-adrenal
invasion
13 (100) 3 (23) 4 (31)
*Feature also included in the Weiss criteria.12 13
HPF, high-power field.
Original article
J Clin Pathol 2008;61:939–944. doi:10.1136/jcp.2008.057067 943
nuclei at microscopy. The cell cycle marker Ki-67 does appear to be
better at distinguishing benign and malignant disease, with a
labelling index .2.5% suggestive of ACC.15 26 The findings in the
present series would support this supposition, with the lowest Ki-
67 (MIB-1) index being 3.7%. Although not a feature of the
RCPath(UK) MDS, we would propose a Ki-67 index as a useful
adjunct in establishing a diagnosis of malignancy, with a good inter-
observer agreement. However, in order for data to be compared
across centres there is a need for standardisation of methods both
for Ki-67 (MIB-1) labelling and to ensure a sufficient number of
tumour cell nuclei are counted (>1000 in the present study).
Ki-67 immunopositivity as a marker of cellular proliferation is
useful in predicting outcome in other malignancies19 and can be
used to guide treatment of neuroendocrine tumours.27 That we
found no relationship between Ki-67 index and survival was
largely due to the highest Ki-67 index occurring in a patient who
presented with signs of feminisation. The biochemistry of
aromatase expression in this man’s tumour is the subject of a
separate report (manuscript in preparation). Nevertheless, the
case illustrates the complex relationship between histopatholo-
gical features of malignancy and clinical manifestations in ACC.
In summary, ACC is a heterogeneous condition with a grim
prognosis. Although the condition is rare, it is possible to
positively impact on clinical care through multicentre collabora-
tions, as evidenced by the results of the recent study of adjuvant
mitotane.28 Standardised histopathological criteria ensure com-
prehensiveness of reporting, offer advantages in predicting
outcome and should facilitate future multicentre endeavours.
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Take-home messages
c Adrenocortical carcinoma is a rare malignancy with a poor
prognosis and a heterogeneous clinical presentation.
c Standardised microscopic criteria such as the Royal College of
Pathologists’ (UK) minimum dataset or Weiss criteria are
useful in assisting in the diagnosis of malignancy and also
possibly in predicting outcome.
c An elevated Ki-67 index is a feature of adrenocortical
carcinoma although is not included in either the Royal College
of Pathologists’ (UK) minimum dataset or Weiss criteria, and
may not necessarily correlate with prognosis.
c Given the rarity of the condition, multicentre efforts are
essential if the prognosis of the malignancy is going to be
improved. Standardised methods of histopathological data
collection will assist future collaborations.
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